1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag

Correction: BBS-Bioactive Bone Substitutes Plc: Annual Report for 2023 has been published

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | March 13, 2024 at 08:00:00 EET

Correction: In the original Company announcement published on 8 March 2024, the sentence in the audit report "The financial statements comprise the balance sheet, income statement, cash flow statement and notes" has been changed to "The financial statements comprise the balance sheets, the income statements, cash flow statements and notes for the group as well as for the parent company." Below is the corrected announcement in its entirety.

BBS-Bioactive Bone Substitutes Plc: Annual Report for 2023 has been published

BBS-Bioactive Bone Substitutes Plc's Annual Report for 2023 has been published on 8 March 2023. The publication is attached to this release and can be found at the Company’s website at https://www.bbs-artebone.fi/
 
The Annual Report includes the English translations of the Board of Director’s Report, the Financial Statements and the Auditors' report. 
 

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS Financial Statements And Board Report 2023

Datum 2024-03-13, kl 07:00
Källa MFN
Bifogade filer
BBS Financial Statements And Board Report 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!